ES2083581T3 - Composiciones de gelificacion reversible y metodos de empleo. - Google Patents

Composiciones de gelificacion reversible y metodos de empleo.

Info

Publication number
ES2083581T3
ES2083581T3 ES91912727T ES91912727T ES2083581T3 ES 2083581 T3 ES2083581 T3 ES 2083581T3 ES 91912727 T ES91912727 T ES 91912727T ES 91912727 T ES91912727 T ES 91912727T ES 2083581 T3 ES2083581 T3 ES 2083581T3
Authority
ES
Spain
Prior art keywords
compositions
reversibly gelling
modified
incorporate
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91912727T
Other languages
English (en)
Inventor
Abhay Joshi
Shulin Ding
Kenneth James Himmelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24149593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2083581(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2083581T3 publication Critical patent/ES2083581T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Cosmetics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

SE PRESENTAN COMPOSICIONES ACUOSAS DE GELIFICACION REVERSIBLE CUYA VISCOSIDAD PASA POR UNOS CAMBIOS SIGNIFICATIVOS EN RESPUESTA A UNOS CAMBIOS SUSTANCIALMENTE SIMULTANEOS DE TEMPERATURA Y PH. LAS COMPOSICIONES ESTAN FORMADAS DE CONCENTRACIONES RELATIVAMENTE BAJAS DE UNA COMBINACION ESTABLE DE AL MENOS UN POLIMERO DE GELIFICACION REVERSIBLE SENSIBLE AL PH Y AL MENOS UN POLIMERO DE GELIFICACION REVERSIBLE SENSIBLE A LA TEMPERATURA. LAS COMPOSICIONES SE PUEDEN FORMULAR DE TAL MODO QUE PRESENTEN UNA TRANSICION DE SOL A GEL EN UNA AMPLIA GAMA DE CONDICIONES Y VISCOSIDADES Y SE PUEDEN MODIFICAR PARA QUE INCORPOREN UN COMPUESTO FARMACEUTICO PARA UTILIZARLAS COMO SISTEMAS DE SUMINISTRO DE MEDICAMENTOS INYECTABLES O POR GOTAS QUE SE GELIFICARAN TRAS LA ADMINISTRACION A UN SISTEMA FISIOLOGICO PARA EL SUMINISTRO CONTINUO DE TALES COMPUESTOS FARMACEUTICOS.
ES91912727T 1990-06-15 1991-06-11 Composiciones de gelificacion reversible y metodos de empleo. Expired - Lifetime ES2083581T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/539,061 US5252318A (en) 1990-06-15 1990-06-15 Reversible gelation compositions and methods of use

Publications (1)

Publication Number Publication Date
ES2083581T3 true ES2083581T3 (es) 1996-04-16

Family

ID=24149593

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91912727T Expired - Lifetime ES2083581T3 (es) 1990-06-15 1991-06-11 Composiciones de gelificacion reversible y metodos de empleo.

Country Status (13)

Country Link
US (2) US5252318A (es)
EP (1) EP0533836B1 (es)
JP (1) JP3181912B2 (es)
AT (1) ATE134508T1 (es)
AU (1) AU8201391A (es)
DE (1) DE69117509T2 (es)
ES (1) ES2083581T3 (es)
IE (1) IE74246B1 (es)
IL (1) IL98320A (es)
NZ (1) NZ238430A (es)
PT (1) PT97977B (es)
WO (1) WO1991019481A1 (es)
ZA (1) ZA914559B (es)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5460834A (en) * 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
JP3135340B2 (ja) 1992-02-25 2001-02-13 森 有一 ドラッグキャリアー
WO1993017664A1 (en) * 1992-03-02 1993-09-16 Alcon Laboratories, Inc. Combinations of cellulosic polymers and carboxy vinyl polymers and their use in pharmaceutical compositions
SE512871C2 (sv) * 1992-08-20 2000-05-29 Santen Oy Oftalmologisk beredning innehållande pilokarpin och ytterligare medel för behandling av okular hypertension
KR100355130B1 (ko) * 1992-09-18 2003-01-30 야마노우치세이야쿠 가부시키가이샤 하이드로겔서방성정제
US5624962A (en) * 1993-04-16 1997-04-29 Wakamoto Pharmaceutical Co., Ltd. Aqueous drug composition having property of reversible thermosetting gelation
WO1995000143A1 (en) * 1993-06-24 1995-01-05 Leiras Oy Composition for ophthalmic use
AU7668894A (en) * 1993-08-13 1995-03-14 Vitaphore Corporation Hydrogel-based microsphere drug delivery systems
KR950007873A (ko) * 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
US5458879A (en) * 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
EP0748342B1 (en) 1994-03-04 2001-10-04 University of Washington Block and graft copolymers and methods relating thereto
SE9401109D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
SE9401108D0 (sv) * 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US5585398A (en) * 1994-07-15 1996-12-17 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
US5603955A (en) * 1994-07-18 1997-02-18 University Of Cincinnati Enhanced loading of solutes into polymer gels
US5840338A (en) * 1994-07-18 1998-11-24 Roos; Eric J. Loading of biologically active solutes into polymer gels
GB9415290D0 (en) 1994-07-28 1994-09-21 Zeneca Ltd Gel formation
US5599534A (en) * 1994-08-09 1997-02-04 University Of Nebraska Reversible gel-forming composition for sustained delivery of bio-affecting substances, and method of use
US5827835A (en) * 1994-08-30 1998-10-27 Alcon Laboratories, Inc. Thermally-gelling emulsions
WO1996006597A1 (en) * 1994-08-30 1996-03-07 Alcon Laboratories, Inc. Thermally-gelling ophthalmic drug delivery vehicles containing cellulose ethers
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5985383A (en) * 1995-03-15 1999-11-16 Acushnet Company Conforming shoe construction and gel compositions therefor
US5955159A (en) * 1995-03-15 1999-09-21 Acushnet Company Conforming shoe construction using gels and method of making the same
US5939157A (en) * 1995-10-30 1999-08-17 Acushnet Company Conforming shoe construction using gels and method of making the same
US5939485A (en) * 1995-06-19 1999-08-17 Medlogic Global Corporation Responsive polymer networks and methods of their use
DE19511322C2 (de) * 1995-03-28 1999-09-02 Mann Gerhard Chem Pharm Fab Sterile Augengele mit einem Gehalt an mittelkettigen Triglyceriden und Verfahren zu deren Herstellung
AU6385796A (en) * 1995-06-16 1997-01-15 Medlogic Global Corporation Responsive polymer networks and methods of their use
JP3766707B2 (ja) * 1995-10-25 2006-04-19 ディップソール株式会社 亜鉛及び亜鉛合金の撥水処理用水溶性組成物及び撥水処理方法
US5766704A (en) * 1995-10-27 1998-06-16 Acushnet Company Conforming shoe construction and gel compositions therefor
US5866120A (en) * 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US6610292B2 (en) * 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5723131A (en) * 1995-12-28 1998-03-03 Johnson & Johnson Vision Products, Inc. Contact lens containing a leachable absorbed material
US6280745B1 (en) 1997-12-23 2001-08-28 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
AU5906898A (en) * 1997-01-02 1998-07-31 Medlogic Global Corporation Responsive polymer networks and methods of their use
WO1998032433A1 (en) * 1997-01-24 1998-07-30 Medlogic Global Corporation Conformable structures
JP2001508802A (ja) * 1997-06-06 2001-07-03 バッテル・メモリアル・インスティチュート 可逆的ゲル化コポリマーと製造方法
GB9718568D0 (en) 1997-09-03 1997-11-05 Chauvin Pharmaceuticals Limite Compositions
DE19744113A1 (de) * 1997-10-06 1999-04-15 Mann Gerhard Chem Pharm Fab Dexamethason-Gel
US20040063678A1 (en) * 1997-10-06 2004-04-01 Bausch & Lomb Incorporated Dexamethasone Gel
US6417247B1 (en) * 1997-10-14 2002-07-09 Beth L. Armstrong Polymer/ceramic composites
JP2001526246A (ja) * 1997-12-23 2001-12-18 アライアンス・ファーマスーティカル・コーポレイション 薬剤送達及び／又は癒着防止のための方法及び組成物
US20040228794A1 (en) * 1998-04-10 2004-11-18 Battelle Memorial Institute Therapeutic agent carrier compositions
US6159483A (en) * 1998-06-01 2000-12-12 Colgate-Palmolive Company Stabilized liquid aqueous composition
US5968480A (en) * 1998-07-09 1999-10-19 Colgate Palmolive Company Oral composition exhibiting enhanced antiplaque efficacy
US6337130B1 (en) 1998-07-30 2002-01-08 Zeneca Limited Acid-triggered release microcapsules
WO2000007603A2 (en) 1998-08-04 2000-02-17 Madash Llp End modified thermal responsive hydrogels
EP1118329A4 (en) * 1998-09-28 2004-12-15 Santen Pharmaceutical Co Ltd LACRYMAL SECRETION PROMOTERS OR OPHTHALMOLOGICAL DROPS CONTAINING NATRIURETIC PEPTIDES AS ACTIVE INGREDIENTS FOR TREATING KERATOCONJUNCTIVITY
US6669927B2 (en) 1998-11-12 2003-12-30 3M Innovative Properties Company Dental compositions
US6312666B1 (en) 1998-11-12 2001-11-06 3M Innovative Properties Company Methods of whitening teeth
US6312667B1 (en) 1998-11-12 2001-11-06 3M Innovative Properties Company Methods of etching hard tissue in the oral environment
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6245740B1 (en) * 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
ATE341345T1 (de) * 1999-06-11 2006-10-15 Cytyc Corp Flüssige gelformulierung zum detektieren von milchkanälen in der brust vor einer chirurgischen ablation des brustgewebes
US6521431B1 (en) 1999-06-22 2003-02-18 Access Pharmaceuticals, Inc. Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments
US20040037891A1 (en) * 1999-10-04 2004-02-26 Karagoezian Hampar L. Synergistic antimicrobial ophthalmic and dermatologic preparations containing chlorite and hydrogen peroxide
US20040234457A1 (en) * 1999-10-19 2004-11-25 The Procter & Gamble Company Methods of preventing and treating SARS using low pH respiratory tract compositions
US20040033260A1 (en) * 1999-10-19 2004-02-19 The Procter & Gamble Company Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc
WO2001041735A2 (en) * 1999-12-07 2001-06-14 Amgen Inc. Thermosensitive biodegradable hydrogels based on low molecular weight pluronics
FR2802097B1 (fr) * 1999-12-14 2002-12-13 Invest S Therapeutiques Essais Composition sous forme de gel prevue pour recevoir un principe actif en solution ou en suspension, notamment pour application sur une muqueuse et procede de fabrication
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
US6660247B1 (en) * 2000-06-23 2003-12-09 Battelle Memorial Institute Multiple stimulus reversible hydrogels
US6303290B1 (en) 2000-09-13 2001-10-16 The Trustees Of The University Of Pennsylvania Encapsulation of biomaterials in porous glass-like matrices prepared via an aqueous colloidal sol-gel process
US7803392B2 (en) * 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
JPWO2002064114A1 (ja) * 2001-02-15 2004-06-10 株式会社三和化学研究所 新規眼科用組成物
DE60233934D1 (de) * 2001-03-21 2009-11-19 Madash Llc Thermisch reversible wasser-in-öl-in-wasser-emulsionen
JP2003089752A (ja) * 2001-03-23 2003-03-28 Canon Inc 刺激応答性ポリマーを含む組成物、それを含むインク組成物、並びに該インク組成物を用いた画像形成方法および装置
FR2823439A1 (fr) * 2001-04-13 2002-10-18 Oreal Composition de bain gelifiantes, relaxantes
DE10132876A1 (de) * 2001-07-06 2003-01-30 Medproject Pharma Entwicklungs Zweiphasige, tropfbare Hydrogele zur Anwendung am Auge
US20080063620A1 (en) * 2001-08-13 2008-03-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel reverse thermo-sensitive block copolymers
US20030082235A1 (en) * 2001-08-13 2003-05-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel reverse thermo-sensitive block copolymers
US6620405B2 (en) 2001-11-01 2003-09-16 3M Innovative Properties Company Delivery of hydrogel compositions as a fine mist
ATE507816T1 (de) * 2001-11-14 2011-05-15 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
AU2002359407B2 (en) 2001-11-14 2008-02-28 Durect Corporation Catheter injectable depot compositions and uses thereof
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
US7204997B2 (en) * 2002-01-29 2007-04-17 Supratek Pharma Inc. Responsive microgel and methods related thereto
AU2003225516A1 (en) * 2002-03-26 2003-10-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Responsive biomedical composites
US20030204180A1 (en) * 2002-04-30 2003-10-30 Kimberly-Clark Worldwide, Inc. Temperature responsive delivery systems
KR20050010792A (ko) * 2002-05-09 2005-01-28 울트라스트 엘엘씨 초음파, 내시경 및 기타 의학적 검사의 조영 증강이나편의를 위한 매질
EP1878447A3 (en) * 2002-05-09 2008-12-31 Ultrast LLC Medium for contrast enhancement or convenience for ultrasonic, endoscopic and other medical examinations
DE10224352A1 (de) * 2002-06-01 2003-12-11 Mueller Schulte Detlef Thermosensitive Polymerträger mit veränderbarer physikalischer Struktur für die biochemische Analytik, Diagnostik und Therapie
JP3891571B2 (ja) * 2002-06-14 2007-03-14 キヤノン株式会社 機能性組成物、それを用いた画像形成方法及び画像形成装置
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
WO2004012703A1 (en) 2002-07-31 2004-02-12 Alza Corporation Injectable depot compositions and uses thereof
CN1684663A (zh) 2002-07-31 2005-10-19 阿尔萨公司 可注射的多模式聚合物储库组合物以及其用途
CA2508303C (en) 2002-12-04 2012-10-23 Santen Pharmaceutical Co., Ltd. Drug delivery system using subconjunctival depot
US20040185013A1 (en) * 2003-01-30 2004-09-23 Burgio Paul A. Dental whitening compositions and methods
US20040151691A1 (en) * 2003-01-30 2004-08-05 Oxman Joel D. Hardenable thermally responsive compositions
US7223826B2 (en) * 2003-01-30 2007-05-29 3M Innovative Properties Company Amide-functional polymers, compositions, and methods
IL155866A0 (en) * 2003-05-12 2003-12-23 Yissum Res Dev Co Responsive polymeric system
CA2839849C (en) 2003-06-13 2017-03-07 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
US7947295B2 (en) 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
TWI336257B (en) 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US7914803B2 (en) 2003-06-13 2011-03-29 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of three polymers
US20050002996A1 (en) * 2003-07-02 2005-01-06 Milan Sojka Sustained release compositions and controlled delivery method
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
DE10350248A1 (de) * 2003-10-28 2005-06-16 Magnamedics Gmbh Thermosensitive, biokompatible Polymerträger mit veränderbarer physikalischer Struktur für die Therapie, Diagnostik und Analytik
GB2408937A (en) * 2003-12-09 2005-06-15 Johnson & Johnson Medical Ltd pH dependent medicinal compositions
GB0329507D0 (en) 2003-12-19 2004-01-28 Guillon Michel Contect lens
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20060089590A1 (en) * 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060147485A1 (en) * 2005-01-04 2006-07-06 Morten Pedersen Oil-in-water formulation of avermectins
DE102005035879A1 (de) * 2005-07-30 2007-02-01 Paul Hartmann Ag Hydrogel
US20070048338A1 (en) * 2005-08-26 2007-03-01 Ladd Byron S Compositions and methods for surface treatment in medical and surgical procedures
US7982066B2 (en) 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
US20070248630A1 (en) * 2006-04-20 2007-10-25 Friden Phillip M Pharmaceutical formulations for iontophoretic methotrexate delivery
CA2652752A1 (en) * 2006-04-20 2007-11-01 Transport Pharmaceuticals, Inc. Pharmaceutical formulations for iontophoretic drug delivery
US20070259021A1 (en) * 2006-05-01 2007-11-08 Friedlaender Mitchell H Compositions, Methods, and Kits for Treating Dry Eye
EP1873205A1 (en) * 2006-06-12 2008-01-02 Corning Incorporated Thermo-responsive blends and uses thereof
EP2158898A1 (en) 2006-06-23 2010-03-03 Aegis Therapeutics LLC Stabilizing alkylglycoside compositions and method thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
PL2056855T3 (pl) 2006-08-31 2015-04-30 Clinuvel Pharmaceuticals Ltd Pochodne alfa-MSH do leczenia fotodermatoz
JPWO2008053810A1 (ja) * 2006-10-30 2010-02-25 三井化学株式会社 ｐＨ応答性ゲルおよびその製造方法、ならびにｐＨ応答性バルブ
RU2340327C1 (ru) * 2007-05-03 2008-12-10 Лев Давидович Раснецов Офтальмологический гель и способ его приготовления
WO2008137872A1 (en) * 2007-05-04 2008-11-13 Personics Holdings Inc. Earguard sealing system i: multi-chamber systems
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物
US8718313B2 (en) * 2007-11-09 2014-05-06 Personics Holdings, LLC. Electroactive polymer systems
DE102007059939A1 (de) 2007-12-12 2009-06-18 Müller-Schulte, Detlef, Dr. Auflösbare, magnetische und unmagnetische Polymerträger zur Abtrennung und Wiedergewinnung von Zellen und Biosubstanzen
US8142870B2 (en) * 2007-12-13 2012-03-27 Personics Holdings Inc. Energy responsive conformal device
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20110130705A1 (en) 2008-03-27 2011-06-02 Clinuvel Pharmaceuticals Limited Therapy for vitiligo
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
KR101101321B1 (ko) * 2008-11-03 2012-01-02 주식회사 엠씨티티 상처 치유를 위한 하이드로 겔 형태의 세포전달용 비히클 및 그 제조방법
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
IT1397132B1 (it) * 2009-12-01 2013-01-04 Alfa Wassermann Spa Composizioni comprendenti antiinfiammatori non steroidei.
WO2011097727A1 (en) 2010-02-10 2011-08-18 Queen's University At Kingston Water with switchable ionic strength
PL2544532T3 (pl) 2010-03-12 2017-08-31 Monsanto Technology Llc Agrochemiczne kompozycje żelowe
WO2012009702A1 (en) 2010-07-15 2012-01-19 Corinthian Ophthalmic, Inc. Method and system for performing remote treatment and monitoring
US10154923B2 (en) 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
MX2013000604A (es) 2010-07-15 2013-07-05 Corinthian Ophthalmic Inc Suministro oftálmico de fármaco.
AU2011278934B2 (en) 2010-07-15 2015-02-26 Eyenovia, Inc. Drop generating device
AU2011342287B2 (en) 2010-12-15 2015-09-17 Greencentre Canada Systems and methods for use of water with switchable ionic strength
GB201100820D0 (en) 2011-01-18 2011-03-02 Guillon Michel Lenses
EP2487185A1 (en) 2011-02-11 2012-08-15 Clinuvel Pharmaceuticals Limited Hexapeptide with improved activity in the repair of cellular DNA of dermal cells
WO2012116013A2 (en) 2011-02-22 2012-08-30 Wackett Lawrence P Silica encapsulated biomaterials
US20160144038A1 (en) 2014-11-20 2016-05-26 Broda International, LLC Water-soluble supramolecular complexes
EP2689774B1 (en) 2011-03-21 2019-01-30 Broda Technologies Co., Ltd Reversely thermo-reversible hydrogel compositions
EP3045163A1 (en) * 2011-04-22 2016-07-20 Alcon Research, Ltd. Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
EP4286400A3 (en) 2011-05-18 2024-06-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
PT3415139T (pt) 2011-06-14 2022-06-20 Neurelis Inc Administração de benzodiazepina
CA2851492A1 (en) 2011-09-22 2013-03-28 Bausch & Lomb Incorporated Ophthalmic gel compositions
US20130101547A1 (en) 2011-10-19 2013-04-25 Allergan, Inc. Thermoresponsive compositions for dermatological use and methods thereof
CN104487028A (zh) 2011-12-12 2015-04-01 艾诺维亚股份有限公司 高模量聚合物喷射器机构、喷射器装置及其使用方法
JP6282231B2 (ja) * 2012-01-23 2018-02-21 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 固化するデポー形成の注入可能な薬物製剤に懸濁される持続放出された生分解性または生体侵食性微小球または微小粒子
EP2890363A1 (en) 2012-08-31 2015-07-08 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
EP2922877B1 (en) 2012-11-20 2018-09-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
WO2014081872A1 (en) 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
US9534236B2 (en) 2013-03-08 2017-01-03 Regents Of The University Of Minnesota Membranes for wastewater-generated energy and gas
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
CN117582516A (zh) 2014-05-28 2024-02-23 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
US10035719B2 (en) 2014-10-15 2018-07-31 Regents Of The University Of Minnesota System and membrane for wastewater-generated energy and gas
HUE048564T2 (hu) 2015-01-26 2020-08-28 Bausch & Lomb Szemészeti szuszpenzió készítmény
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
EP3365022A4 (en) 2015-10-25 2019-07-24 IVIEW Therapeutics, Inc. PHARMACEUTICAL FORMULATIONS WITH IN-SITU FORMULATION
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
KR102643190B1 (ko) 2017-06-10 2024-03-04 아이노비아 인코포레이티드 유체를 취급하기 위한, 그리고 눈에 유체를 전달하기 위한 디바이스들
AU2019205905B2 (en) 2018-01-03 2024-12-12 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of NASH and other disorders
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
JP2021534153A (ja) 2018-08-15 2021-12-09 アイビバ バイオファーマ インコーポレイテッド Ｖｅｇｆおよびｔｇｆベータのマルチキナーゼ阻害剤およびその使用
KR102888598B1 (ko) * 2018-11-26 2025-11-20 아이비바 바이오파마, 인크. 약물 전달을 위한 약학적 생분해성 겔
WO2021119513A1 (en) 2019-12-11 2021-06-17 Eyenovia, Inc. Systems and devices for delivering fluids to the eye and methods of use
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods
CA3221395A1 (en) 2021-06-10 2022-12-15 Neurelis, Inc. Methods and compositions for treating seizure disorders in pediatric patients
WO2025029663A1 (en) * 2023-07-28 2025-02-06 University Of New Hampshire Methods of generating thermoresponsive polysaccharides and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB223166A (en) * 1923-07-11 1924-10-13 Albert Edward Young Improvements in or relating to the sealing of chambers used in the treatment of material in sheet form by air or gas
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4136173A (en) 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4271143A (en) * 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) * 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
CA1141663A (en) * 1979-09-06 1983-02-22 Yukihisa Ishii Ophthalmic solution for intraocular pressure adjustment
ATE6466T1 (de) * 1979-10-26 1984-03-15 Smith And Nephew Associated Companies P.L.C. Autoklavierbare emulsionen.
US4406884A (en) * 1981-06-23 1983-09-27 The Procter & Gamble Company Topical antimicrobial composition
DE3273899D1 (en) * 1981-09-23 1986-11-27 Ciba Geigy Ag A coated absorbant substrate or shaped article, containing a water-soluble and/or volatile active agent
JPS59122422A (ja) * 1982-12-29 1984-07-14 Toko Yakuhin Kogyo Kk 口腔用消炎鎮痛ゲル剤
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
ES8601706A1 (es) * 1983-05-16 1985-11-16 Merck & Co Inc Una composicion farmaceutica
US4474753A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
US4474752A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
JPH0830004B2 (ja) * 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
DE3440352A1 (de) * 1984-11-05 1986-05-07 Dr. Thilo & Co GmbH, 8029 Sauerlach Dry-eye-packung
JPS6267017A (ja) * 1985-09-19 1987-03-26 Sanwa Kagaku Kenkyusho:Kk 被膜形成型揮散性薬物含有軟膏剤
FR2588189B1 (fr) * 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
US4692454A (en) * 1986-02-03 1987-09-08 Warner-Lambert Company Opthalmic use of quinolone antibiotics
US4966773A (en) * 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
DE3721574A1 (de) * 1987-06-30 1989-01-12 Kettelhack Riker Pharma Gmbh Arzneimittel in form von pellets mit enzymatisch kontrollierter arzneistoff-freisetzung
FR2618333B1 (fr) * 1987-07-20 1990-07-13 Merck Sharp & Dohme Composition pharmaceutique et/ou cosmetique a usage topique contenant de la gomme rhamsam
US4917892A (en) * 1988-06-28 1990-04-17 Temple University Encapsulated topical delivery system
JP2670812B2 (ja) * 1988-07-08 1997-10-29 株式会社コーセー 液状化粧料
GB2223166B (en) * 1988-09-29 1992-03-18 American Cyanamid Co Stable ophthalmic preparations containing methazolamide
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use

Also Published As

Publication number Publication date
EP0533836B1 (en) 1996-02-28
DE69117509T2 (de) 1996-09-19
IE912033A1 (en) 1991-12-18
IL98320A0 (en) 1992-06-21
EP0533836A4 (en) 1993-04-21
DE69117509D1 (de) 1996-04-04
JP3181912B2 (ja) 2001-07-03
IL98320A (en) 1995-10-31
US5252318A (en) 1993-10-12
PT97977A (pt) 1992-03-31
JPH05508154A (ja) 1993-11-18
IE74246B1 (en) 1997-07-16
ZA914559B (en) 1992-03-25
EP0533836A1 (en) 1993-03-31
ATE134508T1 (de) 1996-03-15
AU8201391A (en) 1992-01-07
NZ238430A (en) 1993-03-26
WO1991019481A1 (en) 1991-12-26
US5441732A (en) 1995-08-15
PT97977B (pt) 1998-11-30

Similar Documents

Publication Publication Date Title
EP0533836A4 (en) Reversible gelation compositions and methods of use
US5427778A (en) Gel formulations containing growth factors and acrylamide polymer
EP0725628B1 (en) Thermally-gelling drug delivery vehicles containing cellulose ethers
WO2009028764A1 (en) Thermo-reversible coacervate combination gels for protein delivery
ATE536869T1 (de) Auf glucan-film basierte wirkstoffverabreichungssysteme
ATE349202T1 (de) Formulierung auf heparin-, glycosaminoglykan- oder heparinoidbasis und verwendung der formulierung sowie der formulierungsgrundlage
LV5725A4 (lv) Gelu veidojosa oftalmologiska kompozicija
DE69006760D1 (de) Spritzgel-Packung, Verwendung und Darstellung derselben.
ATE358150T1 (de) Abbaubare polyethyleneglycolhydrogele mit kontrollierter halbwertzeit und ihre vorprodukte
EP0735861A1 (en) Tissue moisturizing and antimicrobial compositions
WO2002045683A3 (en) Reversible gelling system for ocular drug delivery
WO1999022716A1 (en) Topical compositions for nsai drug delivery
ES2117825T3 (es) Geles formados por la interaccion de polivinilpirrolidona con derivados de quitosano.
ES2070810T1 (es) Sistemas de hidrogel heterodispersos de liberacion retardada para medicamentos insolubles.
NO923986L (no) Polymer utleveringsanordning for langsom frigjoering av syneresemedisin
NO924104D0 (no) Pulverformulering med flytekontrollert avgivelse
NO166687C (no) Fremgangsmaate for fremstilling av en stabil, vandig, injiserbar opploesning av piroxicam.
AR007649A1 (es) Composicion de relleno para forma de dosis farmaceutica de gelatina blanda y forma de dosis farmaceutica que la comprende
PE20020207A1 (es) Preparaciones de liberacion controlada que comprenden derivados de quinolona y polimeros
EP0208313A3 (en) Gelling agent
US5827835A (en) Thermally-gelling emulsions
EA200200914A1 (ru) Система контроля дозирования для однократного ежедневного приема назначенного ципрофлоксацина
Zalivskaya et al. Comparative characteristics of gel bases for semisolid dosage forms
DE69426765D1 (de) Zusammensetzung zur Viskositätskontrolle von flüssigen Nährmitteln
WO1999017780A8 (de) Dexamethason-gel

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 533836

Country of ref document: ES